
1. J Infect Dis. 2013 Mar 1;207(5):759-67. doi: 10.1093/infdis/jis752. Epub 2012 Dec
7.

Predictors of CD4(+) T-cell counts of HIV type 1-infected persons after virologic
failure of all 3 original antiretroviral drug classes.

Pursuing Later Treatment Option II (PLATO II) Project Team of the Collaboration
of Observational HIV Epidemiological Research Europe (COHERE), Costagliola D,
Ledergerber B, Torti C, van Sighem A, Podzamczer D, Mocroft A, Dorrucci M,
Masquelier B, de Luca A, Jansen K, De Wit S, Obel N, Fätkenheuer G, Touloumi G,
Mussini C, Castagna A, Stephan C, García F, Zangerle R, Duval X, Perez-Hoyos S,
Meyer L, Ghosn J, Fabre-Colin C, Kjaer J, Chêne G, Grarup J, Phillips A, Lodwick 
R, Torti C, Dorrucci M, Günthard HF, Michalik C, Chrysos G, Castagna A.

Collaborators: Audelin A, Castagna A, Costagliola D, Cozzi-Lepri A, De Luca A, De
Wit S, de Wolf F, Dorrucci M, Duval X, Fätkenheuer G, García F, Ghosn J, Günthard
H, Jansen K, Judd A, Ledergerber B, Lo Caputo S, Lodwick R, Masquelier B, Meyer
L, Mocroft A, Mussini C, Noguera-Julian A, Obel N, Paraskevis D, Paredes R,
Pérez-Hoyos S, Phillips A, Pillay D, Podzamczer D, Ramos JT, Stephan C, Tookey
PA, Torti C, Touloumi G, van Sighem A, Warsawski J, Zangerle R, Zangerle R,
Touloumi G, Warszawski J, Meyer L, Dabis F, Krause MM, Ghosn J, Leport C, de Wolf
F, Reiss P, Prins M, Bucher H, Sabin C, Gibb D, Fätkenheuer G, Del Amo J, Obel N,
Thorne C, Mocroft A, Kirk O, Stephan C, Pérez-Hoyos S, Noguera-Julian A, Antinori
A, d'Arminio Monforte A, Brockmeyer N, Ramos J, Battegay M, Rauch A, Mussini C,
Tookey P, Casabona J, Miró JM, Castagna A, de Wit S, Goetghebuer T, Torti C,
Teira R, Garrido M, Haerry D, Weller I, Casabona J, Costagliola D,
d'Arminio-Monforte A, Battegay M, Prins M, de Wolf F, Grarup J, Chene G, Bohlius 
J, Bouteloup V, Bucher H, Cozzi-Lepri A, Dabis F, de Wolf F, Dorrucci M, Egger M,
Engsig F, Furrer H, Kirk O, Lambotte O, Lewden C, Lodwick R, Matheron S, Meyer L,
Miro J, Mocroft A, Obel N, Paredes R, Phillips A, Puoti M, Reekie J, Sabin C,
Scherrer A, Smit C, Sterne J, Thiebaut R, Thorne C, Torti C, von Wyl V, Wittkop
L, Scherrer A, Smit C, Sterne J, Thiebaut R, Thorne C, Torti C, von Wyl V,
Wittkop L.

BACKGROUND: Low CD4(+) T-cell counts are the main factor leading to clinical
progression in human immunodeficiency virus type 1 (HIV-1) infection. We aimed to
investigate factors affecting CD4(+) T-cell counts after triple-class virological
failure.
METHODS: We included individuals from the COHERE database who started
antiretroviral therapy from 1998 onward and who experienced triple-class
virological failure. CD4(+) T-cell counts obtained after triple-class virologic
failure were analyzed using generalized estimating equations.
RESULTS: The analyses included 2424 individuals with a total of 23 922 CD4(+)
T-cell count measurements. In adjusted models (excluding current viral load and
year), CD4(+) T-cell counts were higher with regimens that included boosted
protease inhibitors (increase, 22 cells/µL [95% confidence interval {CI},
3.9-41]; P = .017) or drugs from the new classes (increase, 39 cells/µL [95% CI, 
15-62]; P = .001), compared with nonnucleoside reverse-transcriptase
inhibitor-based regimens. These associations disappeared when current viral load 
and/or calendar year were included. Compared with viral levels of <2.5 log(10)
copies/mL, levels of 2.5-3.5, 3.5-4.5, 4.5-5.5, and >5.5 log(10) copies/mL were
associated with CD4(+) T-cell count decreases of 51, 84, 137, and 186 cells/µL,
respectively (P < .001).
CONCLUSIONS: The approximately linear inverse relationship between log(10) viral 
load and CD4(+) T-cell count indicates that there are likely immunologic benefits
from lowering viral load even by modest amounts that do not lead to undetectable 
viral loads. This is important for patients with low CD4(+) T-cell counts and few
drug options.

DOI: 10.1093/infdis/jis752 
PMID: 23225900  [Indexed for MEDLINE]

